Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $13.00.

Several research firms have recently weighed in on STTK. Wall Street Zen lowered Shattuck Labs from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings upgraded Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Wedbush upped their price objective on Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Cantor Fitzgerald began coverage on Shattuck Labs in a research note on Monday, April 27th. They issued an “overweight” rating on the stock. Finally, TD Cowen reiterated a “buy” rating on shares of Shattuck Labs in a research note on Friday, March 6th.

Shattuck Labs Stock Up 0.2%

Shares of STTK opened at $6.10 on Friday. Shattuck Labs has a 12-month low of $0.71 and a 12-month high of $8.33. The firm has a market capitalization of $467.75 million, a price-to-earnings ratio of -9.68 and a beta of 1.18. The stock’s 50-day moving average price is $6.67 and its 200 day moving average price is $4.62.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. During the same period in the prior year, the business earned ($0.27) EPS. Equities research analysts expect that Shattuck Labs will post -0.51 EPS for the current year.

Insider Buying and Selling at Shattuck Labs

In other news, insider Arundathy N. Pandite sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $6.61, for a total value of $198,300.00. Following the transaction, the insider directly owned 166,219 shares of the company’s stock, valued at $1,098,707.59. The trade was a 15.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 8.79% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Shattuck Labs in the 3rd quarter worth approximately $38,000. AQR Capital Management LLC boosted its holdings in shares of Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after acquiring an additional 31,355 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Shattuck Labs in the 2nd quarter worth approximately $44,000. Squarepoint Ops LLC acquired a new position in shares of Shattuck Labs in the 3rd quarter worth approximately $46,000. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after acquiring an additional 55,000 shares in the last quarter. 58.74% of the stock is owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.